Ludi Yang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Ludi Yang has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
Shengfang Ge
Department of Ophthalmology, Ninth People’s Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, People’s Republic of China
5 shared publicationsJie Yu
Department of Ophthalmology, Shanghai Key Laboratory of Orbital Diseases and Ocular Oncology, Shanghai Ninth People’s Hospital, Shanghai JiaoTong University School of Medicine, Shanghai, China
4 shared publicationsAi Zhuang
Department of Ophthalmology, Shanghai Key Laboratory of Orbital Diseases and Ocular Oncology, Shanghai Ninth People’s Hospital, Shanghai JiaoTong University School of Medicine, Shanghai, China
3 shared publications- Ai Zhuang
Shanghai Jiaotong University School of Medicine, 200093,CHINA. State Key Laboratory of Eye health, Department of Ophthalmology,CHINA. Shanghai Ninth People's Hospital,CHINA. Shanghai Jiao Tong University School of Medicine, 200025,CHINA
3 shared publications Peiwei Chai
Department of Ophthalmology, Shanghai Key Laboratory of Orbital Diseases and Ocular Oncology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200011, China
3 shared publications- Renbing Jia
Department of Ophthalmology, Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, People’s Republic of China
3 shared publications
Latest Publications
- 19 July 2025
- Published by Elsevier in Biotechnology Advances
- Vol. 83, 108649
Epigenetic reprogramming holds promise in enhancing anti-tumor efficacy of CAR T cell therapy
- 19 July 2025
- Published by Elsevier in Biotechnology Advances
- Vol. 83, 108649
Epigenetic reprogramming holds promise in enhancing anti-tumor efficacy of CAR T cell therapy
- 21 February 2025
- Published by Elsevier in Cancer Letters
- Vol. 621, 217583
Neurturin-induced activation of GFRA2-RET axis potentiates pancreatic cancer glycolysis via phosphorylated hexokinase 2
- 21 February 2025
- Published by Elsevier in Cancer Letters
- Vol. 621, 217583
Neurturin-induced activation of GFRA2-RET axis potentiates pancreatic cancer glycolysis via phosphorylated hexokinase 2
- Open Access
- 3 April 2024
- Published by Springer Nature in Experimental Hematology & Oncology
- Vol. 13 (1) , 1-34
Novel insights into TCR-T cell therapy in solid neoplasms: optimizing adoptive immunotherapy
Adoptive immunotherapy in the T cell landscape exhibits efficacy in cancer treatment. Over the past few decades, genetically modified T cells, particularly chimeric antigen receptor T cells, have enabled remarkable strides in the treatment of hematological malignancies. Besides, extensive exploration of multiple antigens for the treatment of solid tumors has led to clinical interest in the potential of T cells expressing the engineered T cell receptor (TCR). TCR-T cells possess the capacity to recognize intracellular antigen families and maintain the intrinsic properties of TCRs in terms of affinity to target epitopes and signal transduction. Recent research has provided critical insight into their capability and therapeutic targets for multiple refractory solid tumors, but also exposes some challenges for durable efficacy. In this review, we describe the screening and identification of available tumor antigens, and the acquisition and optimization of TCRs for TCR-T cell therapy. Furthermore, we summarize the complete flow from laboratory to clinical applications of TCR-T cells. Last, we emerge future prospects for improving therapeutic efficacy in cancer world with combination therapies or TCR-T derived products. In conclusion, this review depicts our current understanding of TCR-T cell therapy in solid neoplasms, and provides new perspectives for expanding its clinical applications and improving therapeutic efficacy.
- 3 April 2024
- Published by Springer Nature in Experimental Hematology & Oncology
- Vol. 13 (1) , 1-34
Open AccessNovel insights into TCR-T cell therapy in solid neoplasms: optimizing adoptive immunotherapy
Adoptive immunotherapy in the T cell landscape exhibits efficacy in cancer treatment. Over the past few decades, genetically modified T cells, particularly chimeric antigen receptor T cells, have enabled remarkable strides in the treatment of hematological malignancies. Besides, extensive exploration of multiple antigens for the treatment of solid tumors has led to clinical interest in the potential of T cells expressing the engineered T cell receptor (TCR). TCR-T cells possess the capacity to recognize intracellular antigen families and maintain the intrinsic properties of TCRs in terms of affinity to target epitopes and signal transduction. Recent research has provided critical insight into their capability and therapeutic targets for multiple refractory solid tumors, but also exposes some challenges for durable efficacy. In this review, we describe the screening and identification of available tumor antigens, and the acquisition and optimization of TCRs for TCR-T cell therapy. Furthermore, we summarize the complete flow from laboratory to clinical applications of TCR-T cells. Last, we emerge future prospects for improving therapeutic efficacy in cancer world with combination therapies or TCR-T derived products. In conclusion, this review depicts our current understanding of TCR-T cell therapy in solid neoplasms, and provides new perspectives for expanding its clinical applications and improving therapeutic efficacy.
- Open Access
- 28 August 2023
- Published by Wolters Kluwer Health in Journal of Craniofacial Surgery
- Vol. 34 (8) , 2379-2383
Publication Trends of Research on Head and Neck Squamous Cell Carcinoma During 2002 to 2022: A 20-Year Bibliometric Study
Background: Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer worldwide. Our study attempted to analyze the research trends in HNSCC and compare contributions from different countries, institutions, journals, and authors. Materials and Methods: The authors extracted publications in this field from 2002 to 2022 from the Web of Science database. Microsoft Excel and VOSviewer were performed to collect data on publication numbers, analyze publication trends, and visualize relevant results. Results: A total of 1903 publications were screened. In the past 20 years, the United States contributed the most publications and citations in the HNSCC research. China ranked second in the number of publications. The Ophthalmic Plastic and Reconstructive Surgery was the most productive journal concerning HNSCC. ESMAELIB of the University of Texas System and ROSENTHAL EL of Stanford University had published the most publications in this field. Keywords were categorized into 3 clusters: basic study, clinical feature study, and treatment-related study. The keywords “reflectance confocal microscopy”, “raman-spectroscopy”, and “confocal laser endomicroscopy” were most frequently emerged in the recent years. Management-related research has been recognized as a potential focus in the HNSCC.
- 28 August 2023
- Published by Wolters Kluwer Health in Journal of Craniofacial Surgery
- Vol. 34 (8) , 2379-2383
Open AccessPublication Trends of Research on Head and Neck Squamous Cell Carcinoma During 2002 to 2022: A 20-Year Bibliometric Study
Background: Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer worldwide. Our study attempted to analyze the research trends in HNSCC and compare contributions from different countries, institutions, journals, and authors. Materials and Methods: The authors extracted publications in this field from 2002 to 2022 from the Web of Science database. Microsoft Excel and VOSviewer were performed to collect data on publication numbers, analyze publication trends, and visualize relevant results. Results: A total of 1903 publications were screened. In the past 20 years, the United States contributed the most publications and citations in the HNSCC research. China ranked second in the number of publications. The Ophthalmic Plastic and Reconstructive Surgery was the most productive journal concerning HNSCC. ESMAELIB of the University of Texas System and ROSENTHAL EL of Stanford University had published the most publications in this field. Keywords were categorized into 3 clusters: basic study, clinical feature study, and treatment-related study. The keywords “reflectance confocal microscopy”, “raman-spectroscopy”, and “confocal laser endomicroscopy” were most frequently emerged in the recent years. Management-related research has been recognized as a potential focus in the HNSCC.
- Open Access
- 28 March 2023
- Published by Springer Nature in Cell Discovery
- Vol. 9 (1) , 1-19
Nuclear PD-L1 promotes EGR1-mediated angiogenesis and accelerates tumorigenesis
Targeting programmed cell death protein ligand 1 (PD-L1) remains one of the most essential immunotherapies in cancer1,2. PD-L1 has been detected in the nucleus in multiple malignancies, playing an oncogenic role independent of immune checkpoint regulation3–5. Howbeit, the regulatory function of nuclear PD-L1 (nPD-L1) remains to be fully understood. Here, we report that nPD-L1 is an endogenous accelerator for cancer angiogenesis. First, we found that an abundant proportion of PD-L1 was distributed within the nucleus of uveal melanoma samples, which is associated with an unfavorable outcome. Moreover, the capacity of promoting angiogenesis was largely attenuated in the nPD-L1-deficient cells both in vivo and in vitro. Mechanistically, nPD-L1 facilitates p-STAT3 binding to the promoter of early growth response-1 (EGR1), resulting in the activation of EGR1-mediated angiogenesis. Therapeutically, the inhibition of histone deacetylase 2 restores the normal acetylation level of PD-L1, blocking its nuclear translocation and thereby attenuating tumor angiogenesis. Conclusively, we reveal that nPD-L1 promotes angiogenesis in malignancies, and provide a novel anti-vascularization strategy through blocking aberrant PD-L1 nuclear translocation for tumor therapy.
- 28 March 2023
- Published by Springer Nature in Cell Discovery
- Vol. 9 (1) , 1-19
Open AccessNuclear PD-L1 promotes EGR1-mediated angiogenesis and accelerates tumorigenesis
Targeting programmed cell death protein ligand 1 (PD-L1) remains one of the most essential immunotherapies in cancer1,2. PD-L1 has been detected in the nucleus in multiple malignancies, playing an oncogenic role independent of immune checkpoint regulation3–5. Howbeit, the regulatory function of nuclear PD-L1 (nPD-L1) remains to be fully understood. Here, we report that nPD-L1 is an endogenous accelerator for cancer angiogenesis. First, we found that an abundant proportion of PD-L1 was distributed within the nucleus of uveal melanoma samples, which is associated with an unfavorable outcome. Moreover, the capacity of promoting angiogenesis was largely attenuated in the nPD-L1-deficient cells both in vivo and in vitro. Mechanistically, nPD-L1 facilitates p-STAT3 binding to the promoter of early growth response-1 (EGR1), resulting in the activation of EGR1-mediated angiogenesis. Therapeutically, the inhibition of histone deacetylase 2 restores the normal acetylation level of PD-L1, blocking its nuclear translocation and thereby attenuating tumor angiogenesis. Conclusively, we reveal that nPD-L1 promotes angiogenesis in malignancies, and provide a novel anti-vascularization strategy through blocking aberrant PD-L1 nuclear translocation for tumor therapy.
- Open Access
- 28 November 2022
- Published by Elsevier in Journal of Pharmaceutical Analysis
- Vol. 13 (1) , 24-38
Epigenetic drug library screening reveals targeting DOT1L abrogates NAD+ synthesis by reprogramming H3K79 methylation in uveal melanoma
- 28 November 2022
- Published by Elsevier in Journal of Pharmaceutical Analysis
- Vol. 13 (1) , 24-38
Open AccessEpigenetic drug library screening reveals targeting DOT1L abrogates NAD+ synthesis by reprogramming H3K79 methylation in uveal melanoma
- Open Access
- 2 October 2022
- Published by Springer Nature in Signal Transduction and Targeted Therapy
- Vol. 7 (1) , 1-21
Extrachromosomal circular DNA: biogenesis, structure, functions and diseases
Extrachromosomal circular DNA (eccDNA), ranging in size from tens to millions of base pairs, is independent of conventional chromosomes. Recently, eccDNAs have been considered an unanticipated major source of somatic rearrangements, contributing to genomic remodeling through chimeric circularization and reintegration of circular DNA into the linear genome. In addition, the origin of eccDNA is considered to be associated with essential chromatin-related events, including the formation of super-enhancers and DNA repair machineries. Moreover, our understanding of the properties and functions of eccDNA has continuously and greatly expanded. Emerging investigations demonstrate that eccDNAs serve as multifunctional molecules in various organisms during diversified biological processes, such as epigenetic remodeling, telomere trimming, and the regulation of canonical signaling pathways. Importantly, its special distribution potentiates eccDNA as a measurable biomarker in many diseases, especially cancers. The loss of eccDNA homeostasis facilitates tumor initiation, malignant progression, and heterogeneous evolution in many cancers. An in-depth understanding of eccDNA provides novel insights for precision cancer treatment. In this review, we summarized the discovery history of eccDNA, discussed the biogenesis, characteristics, and functions of eccDNA. Moreover, we emphasized the role of eccDNA during tumor pathogenesis and malignant evolution. Therapeutically, we summarized potential clinical applications that target aberrant eccDNA in multiple diseases.
- 2 October 2022
- Published by Springer Nature in Signal Transduction and Targeted Therapy
- Vol. 7 (1) , 1-21
Open AccessExtrachromosomal circular DNA: biogenesis, structure, functions and diseases
Extrachromosomal circular DNA (eccDNA), ranging in size from tens to millions of base pairs, is independent of conventional chromosomes. Recently, eccDNAs have been considered an unanticipated major source of somatic rearrangements, contributing to genomic remodeling through chimeric circularization and reintegration of circular DNA into the linear genome. In addition, the origin of eccDNA is considered to be associated with essential chromatin-related events, including the formation of super-enhancers and DNA repair machineries. Moreover, our understanding of the properties and functions of eccDNA has continuously and greatly expanded. Emerging investigations demonstrate that eccDNAs serve as multifunctional molecules in various organisms during diversified biological processes, such as epigenetic remodeling, telomere trimming, and the regulation of canonical signaling pathways. Importantly, its special distribution potentiates eccDNA as a measurable biomarker in many diseases, especially cancers. The loss of eccDNA homeostasis facilitates tumor initiation, malignant progression, and heterogeneous evolution in many cancers. An in-depth understanding of eccDNA provides novel insights for precision cancer treatment. In this review, we summarized the discovery history of eccDNA, discussed the biogenesis, characteristics, and functions of eccDNA. Moreover, we emphasized the role of eccDNA during tumor pathogenesis and malignant evolution. Therapeutically, we summarized potential clinical applications that target aberrant eccDNA in multiple diseases.
- 1 July 2022
- Published by Elsevier in Progress in Retinal and Eye Research
- Vol. 89, 101030
Regulation of epigenetic homeostasis in uveal melanoma and retinoblastoma
- 1 July 2022
- Published by Elsevier in Progress in Retinal and Eye Research
- Vol. 89, 101030
Regulation of epigenetic homeostasis in uveal melanoma and retinoblastoma
- Open Access
- 25 March 2021
- Published by China Anti-cancer Association in Cancer Biology & Medicine
- Vol. 18 (1) , 298-307
Effects of cancer on patients with COVID-19: a systematic review and meta-analysis of 63,019 participants
Effects of cancer on patients with COVID-19: a systematic review and meta-analysis of 63,019 participants
- 25 March 2021
- Published by China Anti-cancer Association in Cancer Biology & Medicine
- Vol. 18 (1) , 298-307
Open AccessEffects of cancer on patients with COVID-19: a systematic review and meta-analysis of 63,019 participants
Effects of cancer on patients with COVID-19: a systematic review and meta-analysis of 63,019 participants